Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-791 in idiopathic pulmonary fibrosis
NL-OMON61535Phase 2Not yet recruiting
- Sponsor
- Contineum Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in idiopathic pulmonary fibrosis (IPF) comparing PIPE-791 with Placebo (2 arms). Primary endpoint: Change in forced vital capacity from baseline to Week 26. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
PIPE-791
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON61535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61535.